FY2025 · ended Dec 31, 2025 · Revenue $13.11M, +29.8% YoY · Filed Mar 12, 2026
Tonix Pharmaceuticals Holding Corp. (TNXP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $13.1 million and a net loss of $124.0 million. Free cash flow was -$103.2 million. As of Jun 30, 2026 it held $176.2 million in cash and investments and $1.3 million in total debt.
Revenue (TTM)
$29.10M
+196.0% vs year-ago TTM
Net income (TTM)
$-159.67M
-96.1% vs year-ago TTM
Operating cash flow (TTM)
$-152.99M
-135.9% vs year-ago TTM
Free cash flow (TTM)
$-158.11M
-141.8% vs year-ago TTM
EPS (TTM)
$-12.53
+38.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
13.41M
+108.3% vs prior year
Net cash
$174.96M
as of Jun 30, 2026
Operating margin
-568.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Berkeley Heights, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1430306
- Former names
- TAMANDARE EXPLORATIONS INC. (until Oct 17, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.8M | — | — |
| Operating income | -$125.7M | -$136.7M | -$118.4M | -$112.1M | -$92.3M |
| Net income | -$124.0M | -$130.0M | -$116.7M | -$110.2M | -$92.3M |
| Diluted EPS | -$14.57 | -$176.60 | -$14,720.25 | -$20.01 | — |
| Operating cash flow | -$99.8M | -$60.9M | -$102.0M | -$98.1M | -$75.6M |
| Free cash flow | -$103.2M | -$61.0M | -$109.9M | -$146.2M | -$110.9M |
| Total assets | $277.2M | $162.9M | $154.5M | $225.7M | $240.9M |
| Total liabilities | $32.0M | $23.3M | $48.9M | $18.5M | $22.2M |
| Stockholders' equity | $245.2M | $139.6M | $105.5M | $207.2M | $218.7M |
| Cash and investments | $207.6M | $98.8M | $24.9M | $120.2M | $178.7M |
| Total debt | $1.3M | $9.3M | $11.9M | $760,000 | $956,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Aug 18, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
All 1000 Tonix Pharmaceuticals Holding Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.